Caren Mason has built a track record of excellence in more than 25 years of healthcare company leadership for large corporations, small public companies and start-up firms in life sciences, health care and medical devices. Her strength in strategy, market development and go-to-market commercialization are welcome contributions to the long term growth of HealthTell.
She has served as CEO of firms including: Verinata Health, a leading provider of non-invasive prenatal genetic testing services, Quidel, a public rapid immunoassay and molecular diagnostics test company and MiraMedica, Inc., a private computer-aided detection mammography systems company. Additionally, Ms Mason held leadership roles at eMed Technologies, GE Healthcare, and Bayer AG/AGFA as well as Baxter Healthcare.
Caren Mason is a graduate of Indiana University. She currently serves on the Board of STAAR Surgical, a public ophthalmic refractive surgery company where she is inaugural Chair of the Quality & Regulatory Committee and a member of the Audit Committee.
Craig Asher has had a successful track record of developing software companies. Over the past ten years he has been a key team member in three successful software startups: Commerce One; Trigo Technologies; and the internal IBM startup for InfoSphere Traceability Server. He has guided major software implementations at over 50 customers in markets including retail, medical products, pharmaceuticals, and general distribution. Following Trigo’s sale to IBM, Craig formed a new startup group within IBM to build a new product for information management software for sensor data. Craig’s role in the new venture was the product strategist, product manager, and implementation manager. Craig has enjoyed co‐chairing several working groups in international standards bodies. He has one issued US patent (7,866,543). He also has extensive experience in marketing strategy, product management, product development, services delivery, business development, and technical sales for growing software companies. Craig did his undergraduate work at Stanford University, and completed his MBA and Masters in Industrial Engineering at Northwestern University.
Dr. Carolyn Compton is an academic pathologist who received her MD and PhD degrees from Harvard Medical School. At ASU, she is the Chief Medical and Science Officer of the National Biomarkers Development Alliance, a member of the Biodesign Institute and the Chief Medical Officer of the Complex Adaptive Systems Initiative. Her research interests are related to colon cancer, bio-banking and biomarkers development.
She was a professor of pathology at Harvard and Massachusetts General Hospital, Chair of Pathology at McGill University from 2000 to 2005, and Director of the Office of Biorepositories and Biospecimen Research at the National Cancer Institute until 2012. She is the past CEO and President of the Critical Path Institute. Compton is an adjunct professor of pathology at both the University of Arizona and Johns Hopkins, and research associate at Mayo Clinic.
Dr. Conley leads new investments for the firm while serving as an active Director on many of Paladin’s portfolio company Boards. Paul joined the Paladin team after more than 15 years of previous R&D and entrepreneurial experience. As founding CEO of BrightScale, he led the commercialization of a patented multi-core microprocessor technology in the HDTV market. As founding CEO of Appfluent Technology, he led the commercialization of patented in-memory distributed database technologies in the enterprise IT market. Prior to taking the entrepreneurial route, he spent nearly a decade in multidisciplinary R&D roles in the areas of high-performance computing, applied physics and biomedical engineering, including postdoctoral positions at the Los Alamos National Laboratory. Paul earned a PhD in Computational Physics and an MS in Bioengineering from UCSD, as well as an MS and BS in Mechanical and Aerospace Engineering from the University of Virginia.